INTRODUCTION
Polycystic ovary syndrome (PCOS) is a heterogeneous endocrinopathy, affecting 6e8% of women of reproductive age. 1 Complications include dyslipidaemia, atherosclerosis, hyperinsulinaemia, and type 2 diabetes. The risk for certain carcinomas such as endometrial and ovarian cancers is increased in PCOS patients. 2 The characteristic of familial aggregation makes PCOS worthy of genetic investigation. 3 In order to identify susceptibility genes, we previously conducted a genome-wide association study (GWAS) in a Chinese Han population. Follow-up studies involving single nucleotide polymorphisms (SNPs) with p value <10e-6 were replicated, with three susceptibility loci confirmed. 4 However, other loci with p value around 10e-5 remain intriguing and may also signal potential risks for PCOS.
Several interesting SNPs with p values ranging from 10e-3 to 10e-5 aggregated in the gene YAP1 on chromosome 11q13 (supplemental table 1). YAP1, carrying the Src homology domain (SH domain) and WW domain, has been shown to bind to a number of signalling proteins. 5 DNA damage caused by oxidative stress would accumulate YAP1 and influence target gene expression and its participation in pro-apoptosis. 6 YAP1 is also a pivotal transcriptional co-activator of the SalvadoreWartseHippo pathway, which governs organ volume and plays an important role in tumours such as breast, lung, and ovarian cancers. Combining our GWAS data and previous information on YAP1, we speculate YAP1 may be a susceptible candidate for PCOS. To determine this, three SNPs (rs11225138, rs11225161, and rs11225166) in YAP1 were genotyped in an additional independent sample of 1115 PCOS patients and 1137 controls for replication study. Metaanalysis was applied to combine our GWAS result and current replication data; genotypeephenotype correlation between the SNPs and PCOS was analysed as well.
SUBJECTS AND METHODS Subjects
A total of 2252 northern Han Chinese women from the Shandong province of China were recruited consecutively at the Center for Reproductive Medicine, Provincial Hospital Affiliated to Shandong University, from June 2009 to May 2011. The 1115 women with PCOS were diagnosed according to the Rotterdam PCOS consensus criteria, which is satisfied by at least two of the three phenotypic criteria after exclusion of other known causes of hyper-androgenaemia and ovulatory dysfunction (including 21-hydroxylase deficiency, congenital adrenal hyperplasia, Cushing's syndrome, androgen-secreting tumours, thyroid disease, and hyperprolactinaemia). The 1137 controls had normal menstrual cycles, and neither hyperandrogenaemia nor polycystic ovaries. Subjects taking oral contraceptives during the past 3 months were excluded. 
Measures

SNP selection
YAP1 contains nine exons and is 122963 bp long. The selected SNPs of the GWAS were integrated to the HapMap database (taken from HapMap, CHB; http://snp.cshl.org/, figure 1). SNPs in YAP1 were selected for replication according to the following criteria: presence in the SNP 6.0 chip, typically representing a block; and minor allele frequency >10% in the Han Chinese population; SNPs of risk allele (OR >1) were captured; of selected SNPs with r 2 <0.8. All selected SNPs were, as noted, statistically different (p<0.05) from our previous GWAS (supplemental table 1). In blocks that contain competing SNPs, the most significant SNP was selected. Ultimately, three SNPsdrs11225138, rs11225161, and rs11225166dwere selected to precede further replication study.
SNP genotyping
Whole-blood samples were obtained by peripheral venous puncture; EDTA was used as the anticoagulant. Genomic DNA was extracted with QIAamp DNA mini kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. All SNPs were analysed by TaqMan-MGB probe assay (Invitrogen Trading, Shanghai, China) using available primers and probes (supplemental table 2). Reactions were performed on 384-well plates, Roche Lightcycle 480, carried out by pre-incubation at 958 for 4 min followed by 45 cycles of denaturation at 958 for 15 s, annealing, extension, and detection for 40 s at 608C. Direct sequencing of 5% randomly selected samples were applied to validate the genotyping assays.
Statistical analysis
Basic characteristics of patients and controls are expressed as means6SD. The caseecontrol genetics power was calculated by Genetic Power Calculator (http://pngu.mgh.harvard.edu/ wpurcell/gpc/). Linkage disequilibrium (LD) was assessed using the Haploview software (Broad Institute, Cambridge, Massachusetts, USA). PLINK (v. Complex traits group.bmj.com on April 12, 2012 -Published by jmg.bmj.com Downloaded from purcell/plink) was applied to calculate the HardyeWeinberg equilibrium (p>0.05), allele frequency differences, and genotype differences. ORs with 95% CIs are presented. Cochran's Q test was used to evaluate the heterogeneity. With no statistically significant heterogeneity observed (p>0.05), meta-analysis of PCOS association for the combined samples was performed by the fixed effects CochraneManteleHaenszel test implemented in PLINK to estimate a summary allelic OR, using the study population as a strata. By the additive effects of risk allele dosage, the logistic regression for disease trait was conducted to exclude the potential confounding effects of age and body mass index. Genetic models were divided into additive (+/+ vs +/À vs À/À), dominant (+/+ plus +/À vs À/À), and recessive (+/+ vs +/À plus À/À). Dominant and recessive models were applied for the phenotype analysis which was compared by one way analysis of variance (ANOVA), SPSS, V.16.0 (SPSS Inc). A value of p<0.05 was regarded as statistically significant.
RESULTS
Characteristics of PCOS and control subjects are summarised in supplemental table 3. The PCOS group was younger than the control group (p<0.001), and the PCOS group had a significantly higher body mass index (p<0.001) than the controls. There were also significantly statistical differences in hormone of LH and T (LH: 10.8864.39 IU/l vs 4.6862.64 IU/l, p<0.001; T: 53.38618.59 ng/dl vs 27.9161.27 ng/dl, p<0.001).
LD and haplotype of three SNPs were calculated by Haploview. Given little or moderate LD at rs11225161 (vs rs11225138, r 2 ¼0.23), rs11225138 (vs rs11225166, r 2 ¼0.33), and rs11225166 (vs rs11225161, r 2 ¼0.17), haplotype associations did not reveal a more significant association than single marker analyses. HardyeWeinberg equilibrium performed by PLINK was higher than 0.05, suggesting no deviation in the PCOS and the control groups in three SNPs.
The allele frequencies of rs11225161, rs11225138, and rs11225166 were presented in table 1. Risk allele A of rs11225161 was significantly higher in the PCOS group (OR 1.32, 95% CI 1.144 to 1.523; p¼0.00014). A nominal difference for rs11225138 allele frequency was found between the PCOS and the control group (OR 1.212, 95% CI 1.056 to 1.391; p¼0.0062). There was no statistical difference for rs11225166 between the two groups (OR 1.097, 95% CI 0.956 to 1.258; p¼0. 19 ). All results were tested by Genetic Power Calculator and reached 0.8 at p¼0.001.
Furthermore, meta-analysis of our previous GWAS and the current replication data was performed. P meta of rs11225161 reached 3.98e-09 (OR 1.393, table 1), implying a genome-wide significance. After adjustment for age and body mass index by logistic regression, the P adjusted value of rs11225161 in replication was 1.53e-04, and combined p¼3.91e-08. Both the rs11225138 and rs11225166 were statistically different after combined analyses (p¼0.0016 and p¼0.0026, respectively) (supplemental table 4).
Genotypes of the three SNPs were also analysed (supplemental table 5). In an additive model, significant differences have been found in rs11225161 (p¼4.4e-4) and rs11225138 (p¼0.022). In a dominant model, similar results were found in rs11225161 (p¼1.5e-4) and rs11225138 (p¼8.6e-3). However, no differences have been found in a recessive model. Of all three models, the dominant model was the most effective for genotype analysis.
The dominant model of genotype was thus used to compare the clinical characteristics in PCOS patients. In rs11225161, there were no statistical differences for FSH, PRL, T, E2, and TSH values between subjects carrying AA+AG and group GG. In the OGTT, the concentration of blood glucose in 30 min (9.0063.79 mmol/l) and 60 min (8.8265 .57 mmol/l) was statistically higher in the risk allele group (p¼0.030 and p¼0.035, respectively, supplemental table 6), suggesting risk allele A in rs11225161 is associated with glucose metabolism. In rs11225138, LH of risk allele was 10.5567.205 IU/l, higher than the homozygote of the major allele frequency group (p¼0.041, supplemental table 7), but the difference was not found in control dominant model analysis (supplemental table 9 ). In addition, in rs11225166, glucose at 30 min also differed in the two groups (p¼0.021, supplemental table 8).
DISCUSSION
Our recently published GWAS identified three susceptibility loci to PCOS having a p value around 10e-05, specifically variants in gene YAP1. 4 In the current research we performed replication studies on SNPs of YAP1 and confirmed the susceptibility of YAP1 to PCOS.
One rs11225161 in the fifth intron of YAP1 has been identified. Meta-analysis of previous GWAS and current replication data showed a genome-wide association significance for allele frequency. The other two SNPsdrs11225138 in the third intron and rs11225166 in the seventh intron of YAP1dwere also statistically significantly different in the adjusted combined study. These data showed variants in YAP1 were associated with PCOS. As reported, polymorphic change in the YAP1 promoter region results in a decrease of YAP1 expression, 11 which implies SNPs in our study remain to be elucidated in functional significance.
YAP1 can bind to a number of transcription factors and serve as a modulator by phosphorylation. As one of the major manifestations of PCOS, ovary enlargement is regulated by some pathways that YAP1 may be involved in. Phosphorylated YAP1 can inhibit co-activation of the TEAD (TEA domain) transcription factor to upregulate pro-growth genes. 12 Moreover, by participation of YAP1/TAZ (transcriptional co-activator with PDZ binding motif), Hippo signalling pathway can act on stem cell compartments and regulate organ size in mammals.
8 YAP1 can also bind to p73 and selectively promote pro-apoptotic genes such as BAX (Bcl-2eassociated X protein) and TP53I3 (tumour protein p53 inducible protein 3). 6 13 This binding could be attenuated by phosphorylation of YAP1 by Akt, 14 which also participates in the endometrial hyperplasia in women with PCOS. 15 Our association study has proved YAP1 to be a novel candidate gene for PCOS, but the underlying function of YAP1 on PCOS still needs further study. By genotype analysis, the risk alleles of these three SNPs in YAP1 seem to have a dominant effect on PCOS patients. Genotypeephenotype correlation analysis also showed that risk allele carriers have severe glucose metabolic disorder. In risk allele carriers of rs11225161, 30 min and 60 min glucose were statistically higher, meanwhile in rs11225166, 30 min glucose was also increased in the risk G group. It has been shown in several studies that patients with PCOS have greater insulin resistance than controls, independent of body mass index. 16 17 In the compensatory phase, there is sufficient insulin secretion for the insulin action impairment. When the b cell function is impaired and no longer able to compensate for the defect mentioned above, glucose intolerance develops, presenting as elevated glucose levels after glucose load. Considering that PCOS and several metabolic disorders (eg, diabetes mellitus, metabolic syndrome, and cardiovascular disease) share insulin resistance as a crucial pathogenetic mechanism, impeded glucose tolerance as shown in the current study suggests that women carrying the risk allele of rs11225161 and rs11225166 are at a high risk of developing these complications. 18 The LH concentration in the rs11225138 risk allele G group was higher than in the non-G PCOS subjects. Increased secretion of LH in PCOS is evidence of anovulation due to the aberrant expression of the receptor, reverse LH/FSH value, and the absence of LH peak. 19 High concentrations of LH will persistently stimulate the ovarian theca cell and result in an over-synthesis of androgen. In addition, excess androstenedione will convert into oestrone, which will exert inhibitory feedback and increase LH release at the pituitary gland level. Given irregular ovulation is the most common phenotype in Chinese PCOS patients, 20 endocrine dysfunction and its relationship with genetic factors is of great clinical importance.
In conclusion, we have identified a new susceptibility gene YAP1 on chromosome 11q13 for PCOS.
